Chipo Mashayamombe-Wolfgarten

Dr. Chipo Mashayamombe-Wolfgarten

Birmingham Womens and Children's Hospital, NHS Trust, Birmingham UK
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
EYElizabeth C. Young
Elizabeth C. Young
BBBenjamin Bowns
Benjamin Bowns
AGAmy Gerrish
Amy Gerrish
MPMichael Parks
Michael Parks
SCSamantha Court
Samantha Court
SAStephanie Allen
Stephanie Allen
A relative haplotype dosage (RHDO)-based method was developed and implemented into routine clinical practice for noninvasive prenatal diagnosis (NIPD) of multiple single-gene disorders: spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and cystic fibrosis. This article describes the experiences of the first 152 pregnancies to have NIPD by RHDO as part of a routine clinical service. Provision of results within a clinically useful time frame (mean, 11 calendar days) was shown to be possible, with a very low failure rate (4%), none being due to a technical failure. Where follow-up confirmatory testing was performed for audit purposes, 100% concordance was seen with the NIPD result, and no discrepancies have been reported. The robust performance of the assay, together with high sensitivity and specificity, demonstrates that NIPD by RHDO is feasible for use in a clinical setting.

30 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
BBBenjamin Bowns
Benjamin Bowns
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
EYElizabeth C. Young
Elizabeth C. Young
SCSamantha Court
Samantha Court
SAStephanie Allen
Stephanie Allen
Retinoblastoma, the most common childhood eye cancer, presents in two forms: heritable or sporadic. Heritable retinoblastoma is caused by a germline mutation in the RB1 gene. Early diagnosis of children at risk of inheriting an RB1 mutation is crucial to achieve optimal clinical outcome. Currently, the majority of genetic testing is performed on newborns, which has multiple disadvantages for both families and the healthcare system. We have developed a non-invasive prenatal diagnosis (NIPD) service for retinoblastoma, available from 8 weeks’ gestation, which uses a combination of massively parallel sequencing (MPS) techniques, dependent on the inheritance model. Detection of paternal or suspected de novo RB1 variants is achieved through amplicon-based MPS. NIPD of a fetus at risk of maternal inheritance is performed using capture-based targeted sequencing and relative haplotype dosage analysis. In addition, we show proof of principle of how capture-based sequencing can be used for de novo variants unsuitable for amplicon-based testing. In total, we report the NIPD of 15 pregnancies, results of which show 100% concordance with all postnatal testing performed at the time of publication (n = 12) with remaining pregnancies ongoing. NIPD of retinoblastoma therefore offers a viable alternative to newborn genetic testing.

6 December 2014 in Journal of The Royal Society Interface
Verified
Journal Article
Open access
PDF file
RSRachel E. Sheldon
Rachel E. Sheldon
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
SSShao-Qing Shi
Shao-Qing Shi
RGRobert E. Garfield
Robert E. Garfield
ASAnatoly Shmygol
Anatoly Shmygol
HBHugo A. van Den Berg
Hugo A. van Den Berg
The smooth muscle cells of the uterus contract in unison during delivery. These cells achieve coordinated activity via electrical connections called gap junctions which consist of aggregated connexin proteins such as connexin43 and connexin45. The density of gap junctions governs the excitability of the myometrium (among other factors). An increase in gap junction density occurs immediately prior to parturition. We extend a mathematical model of the myometrium by incorporating the voltage-dependence of gap junctions that has been demonstrated in the experimental literature. Two functional subtypes exist, corresponding to systems with predominantly connexin43 and predominantly connexin45, respectively. Our simulation results indicate that the gap junction protein connexin45 acts as a negative modulator of uterine excitability, and hence, activity. A network with a higher proportion of connexin45 relative to connexin43 is unable to excite every cell. Connexin45 has much more rapid gating kinetics than connexin43 which we show limits the maximum duration of a local burst of activity. We propose that this effect regulates the degree of synchronous excitation attained during a contraction. Our results support the hypothesis that as labour approaches, connexin45 is downregulated to allow action potentials to spread more readily through the myometrium.

19 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
ESEdward Stone
Edward Stone
CRClaudia Román-Montañana
Claudia Román-Montañana
JAJoseph Abbott
Joseph Abbott
Trevor R.P. ColeTrevor R.P. Cole
Trevor R.P. Cole
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.